The Super Bowl is not just about the game; it's a platform for companies to make bold statements and capture the attention of millions. This year, Hims & Hers, a telehealth giant, is taking center stage with a controversial ad that promises to bridge the gap between the rich and the rest of us.
The Rich Live Longer: A Provocative Truth?
Hims & Hers' ad campaign opens with a bold statement: "Rich people live longer." It then showcases a series of wealthy, wellness-obsessed individuals, from ageless multimillionaires to buff billionaires, alluding to real-life figures like Bryan Johnson and Jeff Bezos. The ad suggests that these individuals have access to a superior healthcare system, one that keeps them youthful and healthy.
But here's where it gets controversial: Hims & Hers presents itself as the solution to this inequality. They claim to offer a different world of healthcare, one with on-demand concierge doctors providing personalized, cutting-edge therapies.
"America's healthcare is divided," says Dan Kenger, the company's chief design officer. "There's an elite, proactive system for the wealthy, and a broken, reactive one for everyone else."
Hims & Hers offers treatments like weight loss and hair restoration, but their ad emphasizes that these services are just the tip of the iceberg. They want you to believe that their platform provides access to the same elite healthcare as the rich, for a price.
Telehealth platforms like Hims & Hers allow patients to pay out of pocket for quick treatment, often for controlled substances like Adderall and testosterone. While they claim to require virtual consultations with medical providers, this detail is often buried in the fine print.
In recent years, the ease of accessing these substances through telehealth has raised concerns. Two telehealth practices have been sanctioned for inappropriately prescribing stimulants, highlighting the potential risks of this new healthcare model.
Last year, Hims & Hers ran a Super Bowl ad focused on democratizing access to GLP-1s for weight loss. This year, they're expanding their offerings to include testosterone and peptides, drugs that have gained popularity among wealthy, high-profile figures.
But here's the catch: the language of "personalized" treatments used by Hims & Hers often refers to compounded versions of name-brand medications, which are not reviewed by the FDA. In fact, the FDA has asked the Justice Department to investigate Hims & Hers for selling compounded GLP-1 pills, raising concerns about consumer safety.
The medical community is worried that telehealth platforms may be facilitating the use of unsafe or unnecessary drugs. The Obesity Society warns against using compounded GLP-1s, as they may lack the appropriate active ingredients.
When asked about the DOJ investigation, Hims & Hers stated that they remain committed to providing safe and affordable care. However, their response to the investigation, posted on X, suggests they will stop selling compounded GLP-1 pills.
The Hims & Hers ad is a clever attempt to capitalize on Americans' frustration with healthcare costs. By narrating the ad with socially conscious rapper Common and using Childish Gambino's "This Is America" in last year's campaign, they position themselves as champions of justice in a broken system.
Pew Research Center data shows that 71% of Americans are worried about healthcare costs, and the ad taps into this sentiment.
At the same time, Americans are increasingly adopting the wellness habits of billionaires, from untested peptides to keto diets. The pursuit of wellness has become a central aspect of American life and the economy, despite the questionable benefits of many of these practices.
Hims & Hers accurately identifies wealth as a key factor in health disparities, but their proposed solution - providing access to elite healthcare - may not be the cure-all it claims to be.
What do you think? Is Hims & Hers offering a legitimate solution to healthcare inequality, or are they exploiting Americans' frustrations for profit? Weigh in and share your thoughts in the comments!
